<?xml version="1.0" encoding="UTF-8"?>
<ref id="B77">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Molina</surname>
    <given-names>J-M</given-names>
   </name>
   <name>
    <surname>Cahn</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Grinsztejn</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Lazzarin</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Mills</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Saag</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial</article-title>. 
  <source>Lancet.</source> (
  <year>2011</year>) 
  <volume>378</volume>:
  <fpage>238</fpage>â€“
  <lpage>46</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60936-7</pub-id>
  <?supplied-pmid 21763936?>
  <pub-id pub-id-type="pmid">21763936</pub-id>
 </mixed-citation>
</ref>
